Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment ; volume:14 ; number:1 ; day:29 ; month:7 ; year:2024 ; pages:1-7 ; date:12.2024
Scientific reports ; 14, Heft 1 (29.7.2024), 1-7, 12.2024
- Creator
-
Castaldo, Alice
Iacotucci, Paola
Bagnasco, Sveva
Fevola, Cristina
Carnovale, Vincenzo
Antonelli, Fabio
Cernera, Gustavo
Gelzo, Monica
Terlizzi, Vito
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-68511-7
- URN
-
urn:nbn:de:101:1-2410132122573.114368056082
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Castaldo, Alice
- Iacotucci, Paola
- Bagnasco, Sveva
- Fevola, Cristina
- Carnovale, Vincenzo
- Antonelli, Fabio
- Cernera, Gustavo
- Gelzo, Monica
- Terlizzi, Vito
- SpringerLink (Online service)
Other Objects (12)
Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novocholesterol synthesis
Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
Targeted therapies to improve CFTR function in cystic fibrosis
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
Vectorized peptidic Inhibitors to rescue F508del-CFTR in Cystic Fibrosis
Lived experiences of individuals with cystic fibrosis on CFTR-modulators
Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novocholesterol synthesis
Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
Targeted therapies to improve CFTR function in cystic fibrosis
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
Vectorized peptidic Inhibitors to rescue F508del-CFTR in Cystic Fibrosis
Lived experiences of individuals with cystic fibrosis on CFTR-modulators
Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novocholesterol synthesis
Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
Targeted therapies to improve CFTR function in cystic fibrosis
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
Vectorized peptidic Inhibitors to rescue F508del-CFTR in Cystic Fibrosis